Director Laurence Marton purchased common stock and related warrants of RenovoRx, Inc. (NASDAQ: RNXT) on March 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The transaction was executed as part of a private placement with a total subscription amount of $10,000.
Under the terms disclosed, Marton acquired 9,720 shares of RenovoRx common stock and 4,860 warrants tied to the same placement. The warrants are exercisable into common shares at $1.9326 per share, may be exercised immediately, and carry an expiration date of March 30, 2029. An alternative expiration condition applies if RenovoRx reports $1.5 million in product sales revenue in a single calendar quarter - in that circumstance the warrants would expire 30 days after such a sales report.
Post-transaction ownership noted in the filing shows Marton holds the 9,720 shares directly through the Laurence Marton Rollover IRA and also owns the 4,860 warrants. The filing identifies the purchase as part of the private placement for the aggregate $10,000 amount.
The insider purchase occurred while RNXT shares were trading at $1.08, a price that represents a 28.56% increase year-to-date. Publicly reported financial metrics referenced in filing-related materials show RenovoRx with a current ratio of 5.83 and more cash than debt on its balance sheet.
Separately, RenovoRx announced a financing event that raised approximately $10 million through a private placement. That financing was led by life science institutional investors and included participation from members of the company’s executive management team and board. Konik Capital Partners, LLC, a division of T.R. Winston & Company, served as the sole placement agent for the transaction.
In addition to the financing, Jones Trading initiated analyst coverage of RenovoRx with a Buy rating and set a price target of $8.00.
Context and implications
The Form 4 filing documents a modest-sized insider investment completed through a private placement structure. The warrants include both a fixed calendar expiration date and a sales-triggered expiration clause tied to the company reaching $1.5 million in product sales within a calendar quarter. The recent capital raise and analyst initiation are noted developments that coincide with the insider purchase.
Information cited in this report is limited to the details disclosed in the Form 4 filing, company statements on the financing, and published analyst coverage. Where information is not specified in those disclosures, this article does not infer additional outcomes or timelines.